Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment-Reference-Cited by-同舟云学术

Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment

Published:2017-04 Issue:4 Volume:7 Page:e554-e554
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer Journal

Author:

Dimopoulos M A,Stewart A K,Masszi T,Špička I,Oriol A,Hájek R,Rosiñol L,Siegel D,Mihaylov G G,Goranova-Marinova V,Rajnics P,Suvorov A,Niesvizky R,Jakubowiak A,San-Miguel J,Ludwig H,Ro S,Aggarwal S,Moreau P,Palumbo A^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

http://www.nature.com/articles/bcj201731.pdf

Reference16 articles.

1. Dimopoulos MA, Richardson PG, Moreau P, Anderson KC . Current treatment landscape for relapsed and/or refractory multiple myeloma. Nat Rev Clin Oncol 2015; 12: 42–54.

2. Moreau P, San Miguel J, Ludwig H, Schouten H, Mohty M, Dimopoulos M et al. ESMO Guidelines Working Group. multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 (Suppl 6): vi133–vi137.

3. Song X, Cong Z, Wilson K . Real world treatment patterns and comorbidities and disease-related complications in patients with multiple myeloma in the United States. Curr Med Res Opin 2016; 32: 95–103.

4. National Comprehensive Care Network (2016). Clinical Practice Guidelines in Oncology. Multiple Myeloma.

5. Kumar SK, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc 2004; 79: 867–874.

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proceedings from the First Onco Summit: LATAM Chapter, 19–20 May 2023, Rio de Janeiro, Brazil;Cancers;2024-09-03

2. Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial;The Lancet Haematology;2024-09

3. Meta-analysis of effectiveness and safety of proteasome inhibitor-dependent maintenance treatment for multiple myeloma a systematic review;Heliyon;2024-08

4. Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real‐world evidence;British Journal of Haematology;2024-07-19

5. Long‐term follow‐up of outcomes including progression‐free survival 2 in patients with transplant‐ineligible multiple myeloma in the real‐world practice: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) database;eJHaem;2024-04-29